Amendments to the Claims

The listing of claims will replace all prior versions, and listings of claims in the application.

1-17. (Cancelled)

18. (Currently amended) A compound having the Formula III:



Formula III

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R_1 is ~~alkyl,~~ haloalkyl, aminoalkyl, $C_{1\text{-}10}$ alkylaminoalkyl, di($C_{1\text{-}10}$)alkylaminoalkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, heteroaralkyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, cyanoalkyl, alkanoylamidoalkyl, alkanoyloxyalkyl, azidoalkyl, alkenyloxyalkyl, or alkoxyalkyl;

R_6 and R_7 taken together are $-OCH_2O-$, $-OCH_2CH_2O-$, $-O-CF_2-O-$, $-CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2-$, $-OCH_2CH_2-$, or $-N(R_9)-CO-O-$; wherein R_9 is optionally substituted lower alkyl;

R_5 and R_8 are independently selected from the group consisting of hydrogen, halogen, haloalkyl, aryl, heterocyclic, heteroaryl, alkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, hydroxyalkyl, nitro, amino, cyano, alkanoylamido, hydroxy, thiol, alkanoyloxy, alkoxy, carboxy, carbonylamido or thioalkoxy;

X is O or S; and

Y is optionally substituted aryl or optionally substituted heteroaryl.

19. (Cancelled)

20. (Previously presented) A compound according to claim 18, or a pharmaceutically acceptable salt thereof, wherein:

Y is 

R_2 is H, alkyl, halo, amino, alkoxy, or nitro; and

R_3 and R_4 are taken together to form a five or six membered carbocyclic or heterocyclic ring.

21. (Previously presented) The compound according to claim 20, or a pharmaceutically acceptable salt thereof, wherein R_3 and R_4 taken together are $-OCH_2O-$, $-OCH_2CH_2O-$, $-O-CF_2-O-$, $-CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2-$, $-O-CH_2-CH_2-$, -N=CH-O-, -NH-CO-O-, -CH=CH-CH=CH-, or -O-CH=CH-.

22. (Previously presented) A compound according to claim 18, wherein said compound is selected from the group consisting of:

2-[2-(Dimethylamino)ethyl]-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone,

2-Ethyl-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone,

2-[2-(1-Imidazolyl)ethyl]-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone,

4-(3,4-Methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone,

2-[2-(1-Piperidinyl)ethyl]-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone,

2[2-(1-Pyrrolidinyl)ethyl]-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone, and

2-[2-(Ethoxycarbonyl)ethyl]-4-(3,4-methylenedioxyphenyl)-6,7-methylenedioxy-1(2H)-phthalazinone;

or a pharmaceutically acceptable salt thereof.

23. (Previously presented) A pharmaceutical composition comprising the compound of claim 18, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier.

24-34. (Cancelled)

35. (Previously presented) The compound according to claim 18, or a pharmaceutically acceptable salt thereof, wherein R_6 and R_7 are taken together to form $-OCH_2O-$, $-OCH_2CH_2O-$ or $-O-CF_2-O-$.

36. (Previously presented) The compound according to claim 20, or a pharmaceutically acceptable salt thereof, wherein R_3 and R_4 are taken together to form $-OCH_2O-$, $-OCH_2CH_2O-$ or $-O-CF_2-O-$.

37. (Cancelled)

38. (New) A compound having the Formula III:



Formula III

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R_1 is alkyl, haloalkyl, aminoalkyl, C_{1-10} alkylaminoalkyl, di(C_{1-10})alkylaminoalkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, heteroaralkyl,

carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, cyanoalkyl, alkanoylamidoalkyl, alkanoyloxyalkyl, azidoalkyl, alkenyloxyalkyl, or alkoxyalkyl;

R_6 and R_7 taken together are $-OCH_2O-$, $-OCH_2CH_2O-$, $-O-CF_2-O-$, $-CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2-$, $-OCH_2CH_2-$, or $-N(R_9)-CO-O-$; wherein R_9 is optionally substituted lower alkyl;

R_5 and R_8 are independently selected from the group consisting of hydrogen, halogen, haloalkyl, aryl, heterocyclic, heteroaryl, alkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, hydroxyalkyl, nitro, amino, cyano, alkanoylamido, hydroxy, thiol, alkanoyloxy, alkoxy, carboxy, carbonylamido or thioalkoxy;

X is O or S;

Y is optionally substituted aryl or optionally substituted heteroaryl; and

provided that when X is O, Y is unsubstituted phenyl, and R_5 and R_8 are hydrogen, then R_1 is not alkyl.

39. (New) A compound having the Formula III:



Formula III

or a pharmaceutically acceptable salt or prodrug thereof, wherein:

R_1 is alkyl, haloalkyl, aminoalkyl, C_{1-10} alkylaminoalkyl, di(C_{1-10})alkylaminoalkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, heteroaralkyl, carbocycloalkyl, heterocycloalkyl, hydroxyalkyl, cyanoalkyl, alkanoylamidoalkyl, alkanoyloxyalkyl, azidoalkyl, alkenyloxyalkyl, or alkoxyalkyl;

R_6 and R_7 taken together are $-OCH_2O-$, $-OCH_2CH_2O-$, $-O-CF_2-O-$, $-CH_2CH_2CH_2-$, $-CH_2CH_2CH_2CH_2-$, $-OCH_2CH_2-$, or $-N(R_9)-CO-O-$; wherein R_9 is optionally substituted lower alkyl;

R_5 and R_8 are independently selected from the group consisting of hydrogen, halogen, haloalkyl, aryl, heterocyclic, heteroaryl, alkyl, alkenyl, alkynyl, aralkyl, aralkenyl, aralkynyl, hydroxyalkyl, nitro, amino, cyano, alkanoylamido, hydroxy, thiol, alkanoyloxy, alkoxy, carboxy, carbonylamido or thioalkoxy;

X is O or S; and wherein:

Y is 

R_2 is H, alkyl, halo, amino, alkoxy, or nitro; and

R_3 and R_4 are taken together to form a five or six membered carbocyclic or heterocyclic ring.

40-42. (Cancelled)